47
Participants
Start Date
October 30, 2009
Primary Completion Date
January 15, 2018
Study Completion Date
January 15, 2018
cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
Memorial Sloan-Kettering Cancer Center, New York
John Hopkins Medical Center, Baltimore
Children's Healthcare of Atlanta at Egleston, Atlanta
MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children, Orlando
Children's Mercy Hospital & Clinics, Kansas City
Md Anderson Cancer Center, Houston
Phoenix Children'S Hospital, Phoenix
University of Colorado Health Sciences Center, Denver
University of Florida, Gainesville
Seattle Children'S Hospital, Seattle
Dana Farber Cancer Institute, Boston
Alberta Children'S Hospital, Calgary
Collaborators (1)
Children's Healthcare of Atlanta
OTHER
Dana-Farber Cancer Institute
OTHER
M.D. Anderson Cancer Center
OTHER
Phoenix Children's Hospital
OTHER
Alberta Children's Hospital
OTHER
University of Colorado, Denver
OTHER
Seattle Children's Hospital
OTHER
Johns Hopkins University
OTHER
Children's Mercy Hospital Kansas City
OTHER
University of Florida
OTHER
Memorial Sloan Kettering Cancer Center
OTHER